These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 16040336

  • 1. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 4. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK.
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [Abstract] [Full Text] [Related]

  • 5. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 6. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 7. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 8. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 9. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

  • 10. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
    Arthritis Res Ther; 2004 Dec; 6(3):R264-72. PubMed ID: 15142273
    [Abstract] [Full Text] [Related]

  • 11. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
    Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A.
    Clin Exp Rheumatol; 2004 Dec; 22(6):756-8. PubMed ID: 15638051
    [Abstract] [Full Text] [Related]

  • 12. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P.
    Arthritis Res Ther; 2006 Dec; 8(4):R131. PubMed ID: 16869978
    [Abstract] [Full Text] [Related]

  • 13. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL.
    Arthritis Res Ther; 2006 Aug; 8(1):R3. PubMed ID: 16356192
    [Abstract] [Full Text] [Related]

  • 15. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G.
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [Abstract] [Full Text] [Related]

  • 16. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M, Graninger WB, Steiner G, Smolen JS.
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [Abstract] [Full Text] [Related]

  • 18. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R.
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [Abstract] [Full Text] [Related]

  • 19. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 20. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.
    Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M.
    Cytokine; 2008 Jun; 42(3):293-7. PubMed ID: 18445529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.